Return on Assets (ROA): Rigel Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds ...

Rigel & Rigel, one of Rome’s longest-standing chiropractic practices, is proudly celebrating 55 years of continuous service, ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. Rigel senior ...

Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year ...

CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...

Rigel Pharmaceuticals (RIGL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports ...

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2023, including sales of ...

The company is teaming up with Eli Lilly on the development of a promising immune disease drug. Rigel will receive an up-front payment of $125 million from Lilly under the new agreement. In addition, ...